Finoriq research workspace
Annovis Bio, Inc. (ANVS) SEC Filings & Filing Highlights
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat. Review ANVS SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer's disease, as well as in open-label phase 3 to treat parkinson's disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania.
- Company
- Annovis Bio, Inc. (ANVS)
- Ticker
- ANVS
- Market Cap
- $59.1M
- Latest Price
- $1.705
- Industry
- Biotech & Pharma
Annovis Bio, Inc. (ANVS) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Annovis Bio, Inc. (ANVS).
| Event | Form | Date |
|---|---|---|
| The following is a brief description of the final voting results for each of the five proposals...On June 17, 2026, Annovis Bio, Inc. (the “Company”) held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”) virtually. At the A... | 8-K5.07 | 2026-06-17 |
| Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying WarrantsAnnovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants | 8-K7.01 | 2026-05-20 |
| The legal opinion of Loeb & Loeb LLP relating to the Shares, Warrants and Warrant Shares is fil...On May 20, 2026, Annovis Bio, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”), dated as of May 2... | 8-K1.01 | 2026-05-20 |
| Annovis Provides Corporate Updates and Reports First Quarter 2026 Financial ResultsAnnovis Provides Corporate Updates and Reports First Quarter 2026 Financial Results | 8-K2.02 | 2026-05-15 |
| Annovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying WarrantsAnnovis Announces $10 Million Underwritten Offering of Common Stock and Accompanying Warrants | 8-K7.01 | 2026-04-10 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.